Dataset Information

Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in patient-derived mutant NPM1 and FLT-ITD-expressing AML cells

ABSTRACT: We treated patient-derived mutant NPM1-and FLT3-ITD expressing AML cells with a chromatin remodeling inhibitor, FHD-286, at a dose of 100 nM, for 48 hours to determine FHD-286-mediated changes to the AML proteome.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Acute Leukemia

SUBMITTER: Antrix Jain

LAB HEAD: Warren Fiskus

PROVIDER: PXD047967 | Pride | 2025-05-06

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	52301_1_EXP_1011_hs_TMT16_prof_plex1_250ng_F01.pepXML	Pepxml
	52301_1_EXP_1011_hs_TMT16_prof_plex1_250ng_F01.raw	Raw
	52301_1_EXP_1011_hs_TMT16_prof_plex1_250ng_F02.pepXML	Pepxml
	52301_1_EXP_1011_hs_TMT16_prof_plex1_250ng_F02.raw	Raw
	52301_1_EXP_1011_hs_TMT16_prof_plex1_250ng_F03.pepXML	Pepxml

Items per page:

1 - 5 of 50

Publications

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Fiskus Warren W Mill Christopher P CP Piel Jessica J Collins Mike M Hentemann Murphy M Cuglievan Branko B Birdwell Christine E CE Das Kaberi K Hou Hanxi H Davis John A JA Jain Antrix A Malovannaya Anna A Kadia Tapan M TM Daver Naval N Sasaki Koji K Takahashi Koichi K Hammond Danielle D Reville Patrick K PK Flores Lauren B LB Loghavi Sanam S Su Xiaoping X DiNardo Courtney D CD Bhalla Kapil N KN

Blood cancer journal 20250315 1

Although treatment with standard frontline therapies, including a FLT3 inhibitor (FLT3i) reduces AML burden and achieves clinical remissions, most patients with AML with FLT3 mutation relapse due to therapy-resistant stem/progenitor cells. The core ATPases, BRG1 (SMARCA4) and BRM (SMARCA2) of the canonical (c) BAF (BRG1/BRM-associated factor) complex is a dependency in AML cells, including those harboring FLT3 mutations. We have previously reported that treatment with FHD-286, a BRG1/BRM ATPases ...[more]

PMID: 40089460

Dataset Information

Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in patient-derived mutant NPM1 and FLT-ITD-expressing AML cells

Dataset's files

Publications

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Project title: Effect of FHD-286 or BRG1/BRM degrader AU15330 on protein expressions in MLL1-rearranged AML cells
2025-04-28 | PXD055994 | Pride

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping features
2009-06-01 | E-GEOD-16015 | biostudies-arrayexpress

Crenolanib in combination with azacitidine abrogates stromal protection and survival of leukemia-initiating cells in FLT3-ITD+ AML
2017-04-03 | GSE86021 | GEO

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping features
2009-06-01 | GSE16015 | GEO

MicroRNA profiling of human acute myeloid leukemia samples from patients characterized for subcellular localization/mutation status of NPM1 and FLT3 mutations
2008-03-14 | E-TABM-429 | biostudies-arrayexpress

Multilineage dysplasia and AML with mutated nucleophosmin
2010-07-30 | E-GEOD-18018 | biostudies-arrayexpress

Multilineage dysplasia and AML with mutated nucleophosmin
2010-07-01 | GSE18018 | GEO

NPM1 mutation-modulated microRNAâmRNA regulation in acute myeloid leukemia [mRNA]
2017-05-03 | E-GEOD-68466 | biostudies-arrayexpress

NPM1 mutation-modulated microRNAâmRNA regulation in acute myeloid leukemia [miRNA]
2017-05-03 | E-GEOD-68467 | biostudies-arrayexpress

NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation
2024-08-14 | GSE274558 | GEO